Campennì Alfredo, Giovanella Luca, Siracusa Massimiliano, Alibrandi Angela, Pignata Salvatore A, Giovinazzo Salvatore, Trimarchi Francesco, Ruggeri Rosaria M, Baldari Sergio
1 Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Nuclear Medicine Unit, University of Messina , Messina, Italy .
2 Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland , Bellinzona, Switzerland .
Thyroid. 2016 Aug;26(8):1101-9. doi: 10.1089/thy.2016.0135. Epub 2016 Jul 8.
Thyroid nodular disease is a very common clinical problem. The diagnostic algorithm includes laboratory tests, thyroid ultrasound (US), thyroid scintigraphy, and, if necessary, US-guided fine-needle aspiration cytology. However, cytology results are reported as indeterminate in a not negligible number of patients. This is a central problem in the workup of patients, since about 55-85% of those undergoing surgery do not have thyroid cancer at final histology diagnosis. The aim of this study was to evaluate prospectively the role of (99m)Tc-methoxy-isobutyl-isonitrile ((99m)Tc-MIBI) thyroid scintigraphy in differentiating malignant from benign thyroid nodules with indeterminate cytology using quantitative analysis.
One hundred five patients affected by nodular thyroid goiter and with a euthyroid or hypothyroid functional status were prospectively evaluated. All patients had a suspicious nodule ≥15 mm in maximal diameter on US. All nodules were "cold" on (99m)Tc-pertechnetate scintigraphy and had a cytological diagnosis of class III or IV according to the Bethesda system. Planar images of the thyroid were acquired 10 and 60 minutes after (99m)Tc-MIBI administration. All cold nodules were MIBI-positive. Using quantitative analysis, the MIBI washout index (WOind) was calculated as a percentage reduction value of mean MIBI nodular uptake between early (+10 minutes) and late (+60 minutes) scans.
Subdividing the patients into positive and negative for malignancy (either including or excluding patients with Hürthle cell adenoma) and performing receiver operating characterist curve analysis, the optimal WOind cutoff in differentiating malignant from benign follicular lesions was set at -19%. The overall sensitivity and specificity of (99m)Tc-MIBI quantitative analysis in identifying patients with malignant lesions was 100% and 90.9%, respectively. However, after excluding patients with Hürthle cell adenomas from the negative patient group, the overall sensitivity and specificity both reached 100%.
The use of MIBI scintigraphy using quantitative analysis in the workup of cold nodules with indeterminate cytology is suggested in order to stratify patient risk for a malignant lesion better, thus reducing the number of patients referred to surgery. Surgical treatment should be planned in those patients with a WOind up to -19%.
甲状腺结节性疾病是一个非常常见的临床问题。诊断方法包括实验室检查、甲状腺超声(US)、甲状腺闪烁扫描,必要时进行超声引导下细针穿刺细胞学检查。然而,在相当数量的患者中,细胞学检查结果被报告为不确定。这是患者检查过程中的一个核心问题,因为在最终组织学诊断中,接受手术的患者中约55 - 85%没有甲状腺癌。本研究的目的是前瞻性评估(99m)锝 - 甲氧基异丁基异腈((99m)Tc - MIBI)甲状腺闪烁扫描在使用定量分析鉴别细胞学检查结果不确定的甲状腺良恶性结节中的作用。
前瞻性评估了105例患有结节性甲状腺肿且甲状腺功能正常或减退的患者。所有患者在超声检查中均有一个最大直径≥15毫米的可疑结节。所有结节在(99m)高锝酸盐闪烁扫描中均为“冷”结节,并且根据贝塞斯达系统细胞学诊断为III类或IV类。在注射(99m)Tc - MIBI后10分钟和60分钟采集甲状腺平面图像。所有冷结节MIBI均为阳性。使用定量分析,计算MIBI洗脱指数(WOind),其为早期(+10分钟)和晚期(+60分钟)扫描之间平均MIBI结节摄取的百分比降低值。
将患者分为恶性阳性和阴性(包括或不包括许特莱细胞腺瘤患者)并进行受试者操作特征曲线分析,鉴别恶性与良性滤泡性病变的最佳WOind临界值设定为 - 19%。(99m)Tc - MIBI定量分析在识别恶性病变患者中的总体敏感性和特异性分别为100%和90.9%。然而,从阴性患者组中排除许特莱细胞腺瘤患者后,总体敏感性和特异性均达到100%。
建议在对细胞学检查结果不确定的冷结节进行检查时使用MIBI闪烁扫描并进行定量分析,以便更好地分层患者发生恶性病变的风险,从而减少转诊手术的患者数量。对于WOind高达 - 19%的患者应计划进行手术治疗。